VIA Pharmaceuticals, Inc. Announces Grant of New Patent Rights - Phosphodiesterase Inhibitors

SAN FRANCISCO--(BUSINESS WIRE)--VIA Pharmaceuticals, Inc. (NASDAQ: VIAP), a biotechnology company focused on the development of compounds for the treatment of vascular inflammation, announced today that the United States Patent and Trademark Office had granted its patent entitled “Cyclic Nucleotide Phosphodiesterase Inhibitors, Preparation and Uses Thereof.” The patent has also been granted in New Zealand, South Africa and India and is pending in other countries.